- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Nostrils.
Displaying page 1 of 1.
EudraCT Number: 2011-004183-29 | Sponsor Protocol Number: DERC-03 | Start Date*: 2014-06-27 | |||||||||||
Sponsor Name:Dermal Laboratories | |||||||||||||
Full Title: A randomised, placebo-controlled trial to investigate the effectiveness of an antimicrobial product in the elimination of Staphylococcus aureus colonisation from the anterior nares of adult subject... | |||||||||||||
Medical condition: Nasal colonisation with Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005286-69 | Sponsor Protocol Number: 7502 | Start Date*: 2015-02-23 |
Sponsor Name:Kuopion yliopistollinen sairaala/Ensihoitokeskus | ||
Full Title: Intranasal fentanyl in pre-hospital analgesia | ||
Medical condition: Patients with trauma, musculoskeletal, stomach or back pain on numeric rating scale at least value 4 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000724-40 | Sponsor Protocol Number: PTC124-GD-006-CF | Start Date*: 2007-09-27 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006340-60 | Sponsor Protocol Number: OPTUK RFCP PRO002.04 | Start Date*: 2007-03-14 |
Sponsor Name:OptiNose UK Ltd | ||
Full Title: A Double Blind, Randomised, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Intranasal Fluticasone Propionate Delivered by the Optinose Device in Adult Pati... | ||
Medical condition: treatment of bilateral nasal polyposis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004830-32 | Sponsor Protocol Number: ICPCT-2011-UA-FF | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:FAES FARMA, S.A. | |||||||||||||
Full Title: Effects of bilastine on nasal volume after allergen-induced rhinitis in patients with allergic rhinitis | |||||||||||||
Medical condition: Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000851-42 | Sponsor Protocol Number: ID-084A201 | Start Date*: 2018-07-27 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis | |||||||||||||
Medical condition: Bilateral nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000460-42 | Sponsor Protocol Number: AK001-002 | Start Date*: 2016-06-29 | |||||||||||
Sponsor Name:Allakos, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis | |||||||||||||
Medical condition: Moderate to severe nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003924-52 | Sponsor Protocol Number: PTC124-GD-009-CF | Start Date*: 2009-04-08 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc | |||||||||||||
Full Title: A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis | |||||||||||||
Medical condition: Nonsense-Mutation-Mediated Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) BE (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000829-27 | Sponsor Protocol Number: LPS16747 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche & Développement | |||||||||||||
Full Title: A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients | |||||||||||||
Medical condition: Chronic rhinosinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) BE (Completed) CZ (Completed) FI (Completed) HU (Completed) SE (Completed) ES (Ongoing) DK (Completed) PT (Completed) PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006854-24 | Sponsor Protocol Number: ALA-AK-CT002 | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:Biofrontera Bioscience GmbH | |||||||||||||
Full Title: A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatme... | |||||||||||||
Medical condition: Actinic keratosis (AK) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004884-24 | Sponsor Protocol Number: X-03016-3271 | Start Date*: 2008-08-04 | |||||||||||
Sponsor Name:MEDA Pharma GmbH & Co. KG | |||||||||||||
Full Title: Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA) | |||||||||||||
Medical condition: This study will investigate the long term effects of Aldara® and Solaraze® on Actinic keratoses (AKs) on the face or scalp. AKs are defined as keratotic macules, papules or plaques with superficia... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005991-41 | Sponsor Protocol Number: OPTUK MSPP PRO002 | Start Date*: 2007-03-12 | |||||||||||
Sponsor Name:OptiNose UK Ltd. | |||||||||||||
Full Title: A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine. | |||||||||||||
Medical condition: Acute Treatment of Migraine with or without Aura | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004349-18 | Sponsor Protocol Number: M-14789-41 | Start Date*: 2022-07-14 | |||||||||||
Sponsor Name:Almirall, S.A. | |||||||||||||
Full Title: A Phase 4, Multi-centre, Randomized, Evaluatorblinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointme... | |||||||||||||
Medical condition: Actinic Keratosis on the Face or Scalp | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004382-83 | Sponsor Protocol Number: ALA-AK-CT009 | Start Date*: 2016-06-09 | |||||||||||
Sponsor Name:Biofrontera Bioscience GmbH | |||||||||||||
Full Title: A randomized, observer-blind, intra-individual phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) in combination with daylight-PDT (photodynamic therapy) in comparison with... | |||||||||||||
Medical condition: Actinic keratosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022054-16 | Sponsor Protocol Number: X-03016-3284 | Start Date*: 2011-09-05 | |||||||||||
Sponsor Name:MEDA Pharma GmbH & Co. KG | |||||||||||||
Full Title: Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cel... | |||||||||||||
Medical condition: This study will compare the long term effects of Aldara® and Solaraze® of the actinic keratoses on the face or scalp. Actinic keratoses (AKs) are defined as keratotic macules, papules or plaques w... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002510-12 | Sponsor Protocol Number: ALA-AK-CT007 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Biofrontera Bioscience GmbH | |||||||||||||
Full Title: A randomized, double-blind, phase III multi-center study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) versus placebo in the field-directed treatment of mild to moderate actinic kerat... | |||||||||||||
Medical condition: Actinic keratosis (AK) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000893-12 | Sponsor Protocol Number: 8302 | Start Date*: 2017-08-31 | |||||||||||||||||||||
Sponsor Name:The Newcastle Upon Tyne Hospitals NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Nasal Airway Obstruction Study | |||||||||||||||||||||||
Medical condition: Deviated Nasal Septum | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
